A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

NCT00298038 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

299

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Encephalopathy

Interventions

DRUG: Rifaximin
DRUG: Placebo

Sponsor

Bausch Health Americas, Inc.